The Unstoppable Dermatology Market
It feels like everyone else in healthcare is pumping the brakes, but dermatology? It's steamrolling ahead. The broader healthcare market's pulling back, dropping by 16% year over year, yet dermatology's M&A scene remains steady. What's driving this momentum?
Take a gander at TUSK Practice Sales' latest Q3 2026 report. Dermatology practices with solid management, diversified services, and hefty EBITDA are the belle of the ball. Demand has shifted hard towards add-ons rather than creating new platforms. It's all about expanding existing empires.
Recapitalization: Fresh Capital, Fresh Competition
This recap wave isn't just a ripple; it's a full-on tide! With a bunch of PE-backed platforms five-plus years deep, ownership and cash are shaking up. Fresh capital flows in, revving up competition among buyers, and dermatology practices are positioned right in the crosshairs. The result? Owners are sitting on real leverage.
"The leverage owners have in this volatile scene is crazy in a good way," quips Ryan Mingus from TUSK Practice Sales. For well-run practices with north of $500K in EBITDA, strategy options are vast.
State Legal Hurdles Reshape Buyer Interest
Here's where things get a bit tangly. With Oregon's SB 951 and California's SB 351, alongside potential similar bills cropping up in another nine states, the map for PE engagement is shifting. These laws complicate how private equity can hold healthcare practices, creating a patchwork of regional availabilities. Practices in unrestricted zones are golden, drawing hungry suitors unafraid of bureaucratic stickiness.
Economic Tenacity and the Debt Dilemma
There's no escaping the tightening economic grip, either. The Federal Reserve's dance with interest rates—currently sitting anywhere between 3.50% to 3.75% with whispers of a possible uptick—has put an edge on PE buyer discipline. They're scrutinous now, with deal structures being scrutinized more than ever with added weight on balance sheets.
- The pivotal forces: Add-on deals are surging as the main game.
- Freshly minted recapitalized players bring more options.
- Interest rates make experienced, selective purchases the norm.
- State laws dictate where deals will flourish—or fizzle.
Strategic Dance For Dermatology Practices
As for dermatologists looking to comprehend selling, it's a maze. From upfront cash to equity bits and post-sale comp plans, understanding these components provides clarity. And why worry about timing? Easy: Recapitulated groups and urge-laden buyers need well-managed, diverse businesses like yours.
With a forecasted market expansion to $128 billion by 2033 and 9,500 daily skin cancer diagnoses driving demand, the opportunity is hefty. There’s no doubt we’ll see a second-half spike in acquisition action this year.
“While healthcare tries to settle its jitters, dermatology just might put on the show of the year,” advises Mingus.
For those holding equity cards, it's time to understand your deck and play smart. The dermatology marketplace isn't losing steam anytime soon. Best have a plan while the interest is high and the offers rolling in!
